Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Barry Ticho Sells 3,884 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now owns 63,962 shares of the company's stock, valued at $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Stoke Therapeutics Price Performance

STOK stock traded up $0.14 during mid-day trading on Monday, reaching $8.29. 964,264 shares of the company's stock were exchanged, compared to its average volume of 840,350. The company has a market cap of $448.31 million, a price-to-earnings ratio of -3.95 and a beta of 0.99. The stock's 50 day moving average is $9.47 and its 200 day moving average is $11.39. Stoke Therapeutics, Inc. has a 12-month low of $6.29 and a 12-month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. On average, research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Remove Ads

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp boosted its holdings in Stoke Therapeutics by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock valued at $1,028,000 after purchasing an additional 1,330 shares during the last quarter. Graham Capital Management L.P. raised its holdings in shares of Stoke Therapeutics by 8.5% in the 4th quarter. Graham Capital Management L.P. now owns 18,634 shares of the company's stock valued at $206,000 after buying an additional 1,453 shares during the period. Gilder Gagnon Howe & Co. LLC lifted its stake in Stoke Therapeutics by 2.0% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company's stock worth $1,021,000 after acquiring an additional 1,791 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Stoke Therapeutics by 6.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company's stock valued at $414,000 after acquiring an additional 2,215 shares during the period. Finally, Rhumbline Advisers increased its stake in Stoke Therapeutics by 6.0% during the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock worth $545,000 after purchasing an additional 2,787 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on STOK shares. Chardan Capital reissued a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. HC Wainwright reissued a "buy" rating and issued a $47.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, March 18th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Stoke Therapeutics has an average rating of "Buy" and an average target price of $23.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.